Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIVAR-NMOSD: Sivelestat for Acute Relapse of Neuromyelitis Optica Spectrum Disorder
jRCT2071260028Phase 1Recruiting
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sivelestat in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by none. Primary endpoint: Incidence of adverse events. Started Aug 2026; status: recruiting.
02
Drugs
sivelestat
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCT2071260028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260028.